Display Settings:

Format

Send to:

Choose Destination

    Cancer Cell. 2008 May;13(5):432-40.

    Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

    Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH.

    University of Minnesota Cancer Center, University of Minnesota, 420 Delaware Street S.E., Minneapolis, MN 55455, USA.

    The pathways by which oncogenes, such as MLL-AF9, initiate transformation and leukemia in humans and mice are incompletely defined. In a study of target cells and oncogene dosage, we found that Mll-AF9, when under endogenous regulatory control, efficiently transformed LSK (Lin(-)Sca1(+)c-kit(+)) stem cells, while committed granulocyte-monocyte progenitors (GMPs) were transformation resistant and did not cause leukemia. Mll-AF9 was expressed at higher levels in hematopoietic stem (HSC) than GMP cells. Mll-AF9 gene dosage effects were directly shown in experiments where GMPs were efficiently transformed by the high dosage of Mll-AF9 resulting from retroviral transduction. Mll-AF9 upregulated expression of 192 genes in both LSK and progenitor cells, but to higher levels in LSKs than in committed myeloid progenitors.

    PMID: 18455126 [PubMed - indexed for MEDLINE]

    PMCID: 2430522

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read